Skip to main content

Table 2 Summary of findings from network meta-analysis across models

From: Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses

Intervention RE informative analysis RE vague analysis FE analysis
RR
(95% CrI) 		SUCRA RR
(95% CrI) 		SUCRA RR
(95% CrI) 		SUCRA
Treatment efficacy
Control
(reference trt) 		1 0.06 1 0.08 1 0.03
INH 3–4 0.81 (0.28–2.23) 0.17 0.80 (0.18–3.29) 0.20 0.82 (0.61–1.09) 0.15
INH-6 0.41 (0.19–0.80) 0.52 0.40 (0.14–1.00) 0.50 0.42 (0.32–0.55) 0.56
INH-9 0.49 (0.07–1.59) 0.46 0.36 (0.03–1.67) 0.56 0.62 (0.26–1.46) 0.31
INH12–72 0.24 (0.11–0.46) 0.89 0.22 (0.08–0.54) 0.84 0.24 (0.17–0.34) 0.97
INH/RPT-3 0.35 (0.10–0.88) 0.67 0.31 (0.07–1.11) 0.65 0.37 (0.21–0.61) 0.68
INH/RFMP 3–4 0.49 (0.19–0.99) 0.42 0.45 (0.13–1.18) 0.44 0.52 (0.36–0.75) 0.38
RFMP/PZA-2 0.31 (0.10–0.78) 0.72 0.29 (0.06–1.01) 0.68 0.32 (0.19–0.52) 0.79
INH/RFMP/PZA-3 0.38 (0.15–0.86) 0.59 0.36 (0.11–1.12) 0.56 0.39 (0.24–0.61) 0.63
Resdev; # DP 41.92; 38 38.0; 38 57.3; 38
DIC 203.88 200.9 213.2
SD 0.44 (0.02–1.06) 0.66 (0.25–1.49) NA
Treatment completion
Intervention OR (95% CrI) SUCRA OR (95% CrI) SUCRA OR (95% CrI) SUCRA
Placebo-12 (reference trt) 1 0.06 1 0.14 1 0.08
Placebo-3 4.17 (1.96–8.60) 0.88 4.15 (1.64–10.45) 0.76 4.44 (3.78–5.23) 0.88
INH-3/4 3.01 (1.39–6.42) 0.68 3.01 (1.15–7.94) 0.68 3.01 (2.68–3.36) 0.68
INH/RPT-3 3.58 (1.40–8.83) 0.79 3.54 (1.17–10.44) 0.84 3.87 (2.56–5.80) 0.95
RFMP/PZA-2 2.44 (1.11–5.36) 0.54 2.45 (0.94–6.50) 0.58 2.28 (1.87–2.77) 0.44
INH/RFMP/PZA-3 2.36 (1.02–5.40) 0.52 2.35 (0.85–6.64) 0.54 2.41 (1.79–3.26) 0.48
INH/RFMP 3–4 3.14 (1.43–6.77) 0.72 3.12 (1.22–8.13) 0.78 3.20 (2.44–4.24) 0.79
RFMP 3–4 3.95 (1.15–13.72) 0.81 3.95 (0.93–17.45) 0.79 4.14 (2.49–6.87) 0.89
Placebo-6 1.94 (0.95–3.88) 0.38 1.93 (0.80–4.67) 0.41 2.00 (1.75–2.29) 0.30
INH-6 1.49 (0.73–2.89) 0.22 1.48 (0.62–3.44) 0.32 1.58 (1.42–1.75) 0.18
INH-9 1.64 (0.57–4.45) 0.29 1.61 (0.46–5.38) 0.31 1.87 (1.23–2.83) 0.43
INH12–72 1.16 (0.59–2.45) 0.11 1.19 (0.52–3.03) 0.07 0.97 (0.87–1.07) 0.01
Resdev; # DP 36.33; 35 35.22; 35 63.93; 35
DIC 274.54 274.06 295.29
SD 0.33 (0.16–0.63) 0.41 (0.20–0.83) NA
  1. Pairwise comparisons versus the reference treatment estimated from network meta-analysis are shown for treatment efficacy and treatment completion. Comparisons from three analyses (RE vague prior, RE informative prior, and FE) are presented as rate ratios (RR) for the efficacy analysis and odds ratios (OR) for the completion analysis, respectively, along with 95% credible intervals. Pairwise comparisons shown in italic font represent statistically significant differences between interventions.  SUCRA values are reported alongside each intervention. Measures of model fit are also provided for each analysis
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us